Drug Profile
Research programme: antibacterials - Taisho Pharmaceutical/Vernalis
Alternative Names: Antibiotics - Taisho Pharmaceutical/VernalisLatest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical; Vernalis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 May 2019 No recent reports of development identified for research development in Bacterial-infections in Japan
- 28 May 2019 No recent reports of development identified for research development in Bacterial-infections in United Kingdom
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals